Sandbrink, Friedhelm;
Murphy, Jennifer L;
Johansson, Melanie;
Olson, Juli L;
Edens, Ellen;
Clinton-Lont, Jamie;
Sall, James;
Spevak, Christopher;
Brown, Nicole;
Guinta, Raquel;
Macedo, Franz;
Nazario, Mitchell;
Pangarkar, Sanjog;
Preston, Samuel;
Prince, Matthew;
Real, Donna Endsley;
Riegleman, David;
Steil, Evan.
In May 2022, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the use of opioids when managing chronic pain. This synopsis summarizes the recommendations that the authors believe are the most important to ...
Singh, Siddharth;
Ananthakrishnan, Ashwin N;
Nguyen, Nghia H;
Cohen, Benjamin L;
Velayos, Fernando S;
Weiss, Jennifer M;
Sultan, Shahnaz;
Siddique, Shazia M;
Adler, Jeremy;
Chachu, Karen A.
Biomarkers are used frequently for noninvasive monitoring and treatment decision making in the management of patients with ulcerative colitis (UC). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the managemen...
Fuxman, Claudia;
Sicilia, Beatriz;
Linares, María Eugenia;
García-López, Santiago;
Sueyro, Ramiro González;
González-Lamac, Yago;
Zabana, Yamile;
Hinojosa, Joaquín;
Barreiro-de Acosta, Manuel;
Balderramo, Domingo;
Balfour, Deborah;
Bellicoso, Maricel;
Daffra, Pamela;
Morelli, Daniela;
Orsi, Marina;
Rausch, Astrid;
Ruffinengo, Orlando;
Torok, Martín;
Sambuellir, Alicia;
Novillos, Abel;
Gomollónt, Fernando;
Paula, Juan Andrés De.
Ulcerative colitis (UC) is a chronic inflammatory disease that compromises the colon, affecting the quality of life of individuals of any age. In practice, there is a wide spectrum of clinical situations. The advances made in the physio pathogenesis of UC have allowed the development of new, more effecti...
Wang, Qiaoyu;
Tao, Hua;
Fei, Zhimin;
Wang, Shuo;
Hu, Xin;
Li, Ling;
Liu, Dong;
Tao, Xia;
Xie, Jian;
Guo, Ruichen;
Zhao, Chengson;
Wang, Rui.
We have updated the guideline for preventing and managing perioperative infection in China, given the global issues with antimicrobial resistance and the need to optimize antimicrobial usage and improve hospital infection control levels. We conducted a comprehensive evaluation of the evidence for prevent...
Hasegawa, Kiyoshi;
Takemura, Nobuyuki;
Yamashita, Tatsuya;
Watadani, Takeyuki;
Kaibori, Masaki;
Kubo, Shoji;
Shimada, Mitsuo;
Nagano, Hiroaki;
Hatano, Etsuro;
Aikata, Hiroshi;
Iijima, Hiroko;
Ueshima, Kazuomi;
Ohkawa, Kazuyoshi;
Genda, Takuya;
Tsuchiya, Kaoru;
Torimura, Takuji;
Ikeda, Masafumi;
Furuse, Junji;
Akahane, Masaaki;
Kobayashi, Satoshi;
Sakurai, Hideyuki;
Takeda, Atsuya;
Murakami, Takamichi;
Motosugi, Utaroh;
Matsuyama, Yutaka;
Kudo, Masatoshi;
Tateishi, Ryosuke.
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in Oct...
Zeng, Mei;
Xia, Jun;
Zong, Zhiyong;
Shi, Yi;
Ni, Yuxing;
Hu, Fupin;
Chen, Yijian;
Zhuo, Chao;
Hu, Bijie;
Lv, Xiaoju;
Li, Jiabin;
Liu, Zhengyin;
Zhang, Jing;
Yang, Wenjie;
Yang, Fan;
Yang, Qiwen;
Zhou, Hua;
Li, Xin;
Wang, Jianhua;
Li, Yimin;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
Zeng, Mei;
Xia, Jun;
Shi, YI;
Ni, Yuxing;
Fupin, Hu;
Chen, Yijian;
Li, Jiabin;
Zhang, Jing;
Yang, Fan;
Li, Xin;
Li, Yimin;
Wu, Anhua;
Wu, Depei;
Qiu, Haibo;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
